Laboratory Oncology Unit, Dr B.R.A.IRCH, All India Institute of Medical Sciences (AIIMS), Ansari Nagar, New Delhi, 110029, India.
Medical Oncology Department, National Cancer Institute, AIIMS, Jhajjar, Haryana, India.
Clin Transl Oncol. 2021 Nov;23(11):2206-2219. doi: 10.1007/s12094-021-02635-4. Epub 2021 May 15.
Cancer genomics has evolved over the years from understanding the pathogenesis of cancer to screening the future possibilities of cancer occurrence. Understanding the genetic profile of tumors holds a prognostic as well as a predictive value in this era of therapeutic surveillance, molecular remission, and precision medicine. Identifying molecular markers in tumors is the current standard of approach, and requires an efficient combination of an accessible sample type and a profoundly sensitive technique. Liquid biopsy or cell-free DNA has evolved as a novel sample type with promising results in recent years. Although cell-free DNA has significant role in various cancer types, this review focuses on its application in Non-Hodgkin's Lymphoma. Beginning with the current concept and clinical relevance of minimal residual disease in Non-Hodgkin's lymphoma, we discuss the literature on circulating DNA and its evolving application in the realm of cutting-edge technology.
肿瘤基因组学多年来的发展历程，从癌症发病机制的研究，到未来癌症发生可能性的筛查。在治疗监测、分子缓解和精准医学的时代，了解肿瘤的遗传特征具有预后和预测价值。在肿瘤中识别分子标志物是目前的标准方法，需要将易于获取的样本类型与高度敏感的技术有效地结合起来。液体活检或游离 DNA 作为一种新型样本类型，近年来取得了有前景的结果。虽然游离 DNA 在各种癌症类型中具有重要作用，但本综述重点讨论其在非霍奇金淋巴瘤中的应用。本文从非霍奇金淋巴瘤中微小残留病的当前概念和临床相关性开始，讨论了循环 DNA 的文献及其在尖端技术领域的应用进展。
